Helix BioPharma Corp. faced a significant decline in its stock value, raising concerns among investors.
In yesterday's trading session, Helix BioPharma Corp. (HBP.TO) saw its stock plummet by 6.75%, closing at CA$1.52. This decline comes amid ongoing financial challenges and recent capital-raising efforts that may not have inspired investor confidence.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$70.27M
52W high
$3.00
52W low
$0.85
1W change
-3.16%
Beta
-0.14
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 171.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+171.7% Upside
Current Price
C$0.92
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
109.6%
Annualized
90-Day Vol
76.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.77
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.87 | C$0.59 – C$1.27 |
| 60 trading days | C$0.82 | C$0.48 – C$1.39 |
| 90 trading days | C$0.77 | C$0.40 – C$1.48 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should closely monitor Helix BioPharma's financial health and market positioning, especially in light of its recent stock performance and capital-raising activities.
Stock down 6.75% in one day
The market cap of Helix BioPharma now stands at CA$116 million, reflecting investor concerns over its financial trajectory.
Bull case
If Helix BioPharma can successfully execute its capital-raising strategy and advance its therapeutic programs, it might regain investor confidence and stabilize its stock price.
Bear case
On the flip side, continued financial losses and a lack of positive news could lead to further declines in stock value, as investors remain wary of the company's long-term viability.
Recent Performance
Advertisement
Helix BioPharma's stock decline of 6.75% yesterday marks a troubling trend for investors. The company's market cap has shrunk to CA$116 million, raising questions about its financial stability and future growth prospects.
Financial Context
Despite recent efforts to raise capital, including a private placement of shares, Helix BioPharma reported a net loss of CA$5.2 million for the fiscal year ended July 31, 2025. This financial backdrop may have contributed to the stock's poor performance as investors weigh the company's ability to recover.
Looking Ahead
Investors are advised to keep a close eye on Helix BioPharma's upcoming financial statements and any announcements regarding its therapeutic programs. The success of these initiatives will be crucial in determining whether the stock can rebound from its recent lows.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
